BACKGROUND: Experiments in animal models suggest that neuronal plasticity can be enhanced by dopaminergic receptor activation. The present study tested whether stimulation-induced plasticity of human motor cortex after low-frequency repetitive transcranial magnetic stimulation (rTMS) could be potentiated by a single oral dose of the combined D1/D2 receptor agonist pergolide. METHODS: In a randomized, double-blind, placebo-controlled cross-over design, nine healthy young volunteers received .125 mg pergolide or placebo 2 hours before 1 Hz rTMS was applied for 20 min to the left primary motor cortex. In a control experiment 7 subjects received .125 mg pergolide 2 hours before sham rTMS. We used single-pulse TMS at rest to assess corticospinal excitability before and up to 24 min after rTMS. RESULTS:Suppression of corticospinal excitability by 1 Hz rTMS was more pronounced after pergolide intake compared with placebo and lasted approximately 20 min after pergolide but only 5 min after placebo. No change of corticospinal excitability could be observed when sham rTMS was performed after pergolide intake. CONCLUSIONS: The results suggest a possible role for dopaminergic potentiation of rTMS-induced neuroplasticity in experimental or therapeutic applications and should be considered when rTMS is applied in patients under medication with dopamine agonists or antagonists.
RCT Entities:
BACKGROUND: Experiments in animal models suggest that neuronal plasticity can be enhanced by dopaminergic receptor activation. The present study tested whether stimulation-induced plasticity of human motor cortex after low-frequency repetitive transcranial magnetic stimulation (rTMS) could be potentiated by a single oral dose of the combined D1/D2 receptor agonist pergolide. METHODS: In a randomized, double-blind, placebo-controlled cross-over design, nine healthy young volunteers received .125 mg pergolide or placebo 2 hours before 1 Hz rTMS was applied for 20 min to the left primary motor cortex. In a control experiment 7 subjects received .125 mg pergolide 2 hours before sham rTMS. We used single-pulse TMS at rest to assess corticospinal excitability before and up to 24 min after rTMS. RESULTS: Suppression of corticospinal excitability by 1 Hz rTMS was more pronounced after pergolide intake compared with placebo and lasted approximately 20 min after pergolide but only 5 min after placebo. No change of corticospinal excitability could be observed when sham rTMS was performed after pergolide intake. CONCLUSIONS: The results suggest a possible role for dopaminergic potentiation of rTMS-induced neuroplasticity in experimental or therapeutic applications and should be considered when rTMS is applied in patients under medication with dopamine agonists or antagonists.
Authors: Katia Monte-Silva; David Liebetanz; Jessica Grundey; Walter Paulus; Michael A Nitsche Journal: J Physiol Date: 2010-07-26 Impact factor: 5.182